William Blair Investment Management’s PTC Therapeutics PTCT Stock Holding History

William Blair Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$141M	Buy	+1,722,688	New	+$124M	0.42%	73

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

William Blair Investment Management's PTCT Position: Q2 2026 in Review

William Blair Investment Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 1,722,688 shares worth $141M. The stake represents 0.42% of the portfolio and ranks #73 among its holdings.

228 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

William Blair Investment Management held 1,722,688 shares of PTC Therapeutics worth $141M as of Q2 2026.
PTC Therapeutics was a new William Blair Investment Management position in Q2 2026.
PTC Therapeutics made up 0.42% of William Blair Investment Management's portfolio in Q2 2026, its #73 holding.
228 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on William Blair Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.